Stocks Health care CRDL
NASDAQ · Health careCardiol Therapeutics Inc. (CRDL)
It posted a net loss of CA$33.8M. In fiscal 2025 capital spending exceeded operating cash flow by CA$23.9M. At December 31, 2025 it held CA$21.4M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on March 31, 2026.
Key facts about Cardiol Therapeutics Inc.
- Net worth
- Cardiol Therapeutics Inc. has a market value (market cap) of $120.3M at the latest share price, and shareholders' equity of CA$17.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2021 revenue was CA$78.8K, with a net loss of CA$31.6M.
- Cash flow
- In fiscal 2025 operations used CA$23.9M of cash.
- Latest report
- The latest periodic report (annual report (Canadian issuer), 40-F) was filed with the SEC on March 31, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Cardiol Therapeutics Inc. does
Cardiol Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRDL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -CA$33.8M | -CA$0.39 | -CA$23.9M |
| 2024 | n/a | -CA$36.7M | -CA$0.51 | -CA$25.1M |
| 2023 | n/a | -CA$28.1M | -CA$0.44 | -CA$25.2M |
| 2022 | n/a | -CA$30.9M | -CA$0.49 | -CA$27.3M |
| 2021 | CA$78.8K | -CA$31.6M | -CA$0.73 | -CA$23.6M |
| 2021 | n/a | -CA$20.6M | -CA$0.69 | -CA$9.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Cardiol Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- November 3, 2026
- November 3, 2026Form SUPPL filing SUPPL
- September 23, 2026Passive stake changed SCHEDULE 13G/A
- September 23, 2026
- September 16, 2026Form SUPPL filing SUPPL
- September 16, 2026Form F-10/A filing F-10/A
- September 16, 2026
- September 15, 2026
- September 11, 2026
Insider trades
What the people running Cardiol Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns CRDL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| MMCAP International Inc. SPC13G, passive with 1 related filers | 17.6% | August 14, 2026 |
| Tejara Capital Ltd13G, passive | 5.3% | September 23, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 52 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| MMCAP International Inc. SPC | 15,598,560 | +246,243 |
| Tejara Capital Ltd | 5,113,822 | -16,300 |
| Ikarian Capital, LLC | 3,325,000 | +600,000 |
| Boothbay Fund Management, LLC | 975,721 | +180,840 |
| Citadel Advisors LLC | 796,529 | -23,375 |
| Renaissance Technologies LLC | 772,837 | +543,031 |
| Two Sigma Investments, LP | 746,937 | +212,726 |
| Integrity Alliance, LLC. | 388,492 | -76,533 |
| Morgan Stanley | 355,030 | +104,609 |
| Goldman Sachs Group Inc | 333,900 | +1,500 |
| Pvg Asset Management Corp | 107,165 | 0 |
| 1832 Asset Management L.P. | 100,000 | 0 |
| Mgo One Seven LLC | 100,000 | 0 |
| Summit Financial, LLC | 99,109 | -4,950 |
| Jane Street Group, LLC | 53,416 | -73,541 |
| Jpmorgan Chase & Co | 48,077 | 0 |
| Geode Capital Management, LLC | 42,196 | -10,239 |
| Marble Harbor Investment Counsel, LLC | 39,900 | 0 |
| Boyer Financial Services, Inc. | 34,100 | +11,000 |
| Quadrature Capital Ltd | 30,566 | -17,321 |
Insiders
Questions about CRDL
What does Cardiol Therapeutics Inc. do?
Cardiol Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as CRDL. Its shares trade on NASDAQ under the ticker CRDL.
What is Cardiol Therapeutics Inc.'s net worth?
Cardiol Therapeutics Inc. has a market value (market cap) of $120.3M at the latest share price, and shareholders' equity of CA$17.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cardiol Therapeutics Inc. profitable?
No. In fiscal 2025 it reported a net loss of CA$33.8M.
When did Cardiol Therapeutics Inc. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 3, 2026.
Similar companies
Compare CRDL with
Follow CRDL
Get an email when Cardiol Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cardiol Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.